407 related articles for article (PubMed ID: 37566239)
1. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
Reddy DS; Mbilinyi RH; Estes E
Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine insights into neurosteroid therapy for postpartum depression.
Reddy DS
Trends Mol Med; 2023 Dec; 29(12):979-982. PubMed ID: 37541828
[TBL] [Abstract][Full Text] [Related]
3. [GABAergic approach of postpartum depression: A translational review of literature].
Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
[TBL] [Abstract][Full Text] [Related]
4. Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.
Reddy DS
J Neuroendocrinol; 2022 Feb; 34(2):e13028. PubMed ID: 34506047
[TBL] [Abstract][Full Text] [Related]
5. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
Lüscher B; Möhler H
F1000Res; 2019; 8():. PubMed ID: 31275559
[TBL] [Abstract][Full Text] [Related]
6. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
[TBL] [Abstract][Full Text] [Related]
7. Brexanolone for postpartum depression.
Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
[TBL] [Abstract][Full Text] [Related]
8. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
Leader LD; O'Connell M; VandenBerg A
Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
[TBL] [Abstract][Full Text] [Related]
9. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
10. Evaluating brexanolone for the treatment of postpartum depression.
Payne JL
Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
Frieder A; Fersh M; Hainline R; Deligiannidis KM
CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
[TBL] [Abstract][Full Text] [Related]
12. Brexanolone to Treat Postpartum Depression in Adult Women.
Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
[TBL] [Abstract][Full Text] [Related]
13. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
Powell JG; Garland S; Preston K; Piszczatoski C
Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
[No Abstract] [Full Text] [Related]
14. Brexanolone for the treatment of patients with postpartum depression.
Morrison KE; Cole AB; Thompson SM; Bale TL
Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
[TBL] [Abstract][Full Text] [Related]
15. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.
Rupprecht R; Pradhan AK; Kufner M; Brunner LM; Nothdurfter C; Wein S; Schwarzbach J; Puig X; Rupprecht C; Rammes G
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1477-1487. PubMed ID: 36574032
[TBL] [Abstract][Full Text] [Related]
16. Allopregnanolone in Postpartum Depression.
Pinna G; Almeida FB; Davis JM
Front Glob Womens Health; 2022; 3():823616. PubMed ID: 35558166
[TBL] [Abstract][Full Text] [Related]
17. Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression.
Rudzinskas SA; Mazzu MA; Schiller CE; Meltzer-Brody S; Rubinow DR; Schmidt PJ; Goldman D
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372414
[TBL] [Abstract][Full Text] [Related]
18. Neurosteroid Modulation of Synaptic and Extrasynaptic GABA
Mitchell SJ; Phillips GD; Tench B; Li Y; Belelli D; Martin SJ; Swinny JD; Kelly L; Atack JR; Paradowski M; Lambert JJ
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672476
[TBL] [Abstract][Full Text] [Related]
19. Development of neuroactive steroids for the treatment of postpartum depression.
Gunduz-Bruce H; Takahashi K; Huang MY
J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
[TBL] [Abstract][Full Text] [Related]
20. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond.
Zorumski CF; Paul SM; Covey DF; Mennerick S
Neurobiol Stress; 2019 Nov; 11():100196. PubMed ID: 31649968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
